Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Loxo Oncology
Biotech
AACR: Lilly challenges Amgen, Mirati with early KRAS data
KRAS inhibitors arrived on the market in 2021 to much fanfare—but if you ask Eli Lilly’s Loxo unit, the therapies have left much to be desired.
Annalee Armstrong
Apr 17, 2023 2:30pm
Lilly, with Alzheimer's in its sights, forms neuroscience unit
Aug 17, 2021 8:00am
Lilly bets $70M upfront on immuno-oncology pact with Kumquat
Jul 29, 2021 8:40am
Ex-Lilly R&D lead launches cancer biotech with Novartis alum
Apr 27, 2021 7:20am
Lilly cancer R&D chief Bilenker quits, handing reins to deputy
Feb 1, 2021 9:15am
Lilly gives $60M to Merus, ties in $1.6B in biobucks
Jan 19, 2021 7:55am
